AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20923256 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84) 100 µg once daily for 36 months
Number of subjects: 0
Study 20923544 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (YN968D1) 850 mg once daily
Number of subjects: 46
Study 20923544 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (YN968D1) 750 mg once daily
Number of subjects: 46
Study 20923561 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (Group 1)
Number of subjects: 51
Study 20923561 — intervention group
Group type: COMPARATOR
Intervention: CKD patients with e-GFR ≤ 90 ml/min (Group 2)
Number of subjects: 51
Study 20923561 — intervention group
Group type: COMPARATOR
Intervention: CKD patients with 60 ml/min ≤ e-GFR < 90 ml/min (Group 3)
Number of subjects: 51
Study 20923561 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD patients with 15 ml/min ≤ e-GFR < 60 ml/min (Group 4)
Number of subjects: 51
Study 20923629 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline augmentation of pharmacotherapy
Number of subjects: 0
Study 20924570 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppository containing 1,200 mg miconazole
Number of subjects: 20
Study 20924570 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 20925545 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dystrophin transgene delivery
Number of subjects: 6
Study 20925950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocapsiate (DCT) 9 mg/day
Number of subjects: 33
Study 20925950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20925950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocapsiate (DCT) 3 mg/day
Number of subjects: 33
Study 20926522 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified sorghum-based meal
Number of subjects: 23
Study 20926522 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 23
Study 20926522 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic P. falciparum parasitemia
Number of subjects: 23
Study 20926537 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal interventions (specific hormones not detailed)
Number of subjects: 0
Study 20926818 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry treatment (one eye randomized to treatment)
Number of subjects: 10
Study 20926818 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry assessments every 6 months over 24 months
Number of subjects: 10
Study 20926818 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry assessments
Number of subjects: 10
Study 20926818 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth of GA lesion area
Number of subjects: 10
Study 20927368 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI of the right coronary artery (RCA) and vessel wall (MR-CVW)
Number of subjects: 48
Study 20930086 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous MSC infusion
Number of subjects: 2
Study 20930628 — intervention group
Group type: EXPERIMENTAL
Intervention: IDO inhibitors (oral administration)
Number of subjects: 0
Study 20930628 — intervention group
Group type: COMPARATOR
Intervention: High IDO expression in tumor cells
Number of subjects: 0
Study 20932222 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg to 120 mg daily
Number of subjects: 667
Study 20932224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salmon calcitonin
Number of subjects: 0
Study 20932224 — intervention group
Group type: COMPARATOR
Intervention: Nasal formulation of salmon calcitonin
Number of subjects: 0
Study 20932316 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 500
Study 20932316 — intervention group
Group type: COMPARATOR
Intervention: Medically treated controls
Number of subjects: 500
Study 20932316 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed controls
Number of subjects: 500
Study 20934233 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (150 mg/m(2))/oxaliplatin (85 mg/m(2)) followed by etoposide (100 mg/m(2)×3)/carboplatin (AUC 6)
Number of subjects: 26
Study 20935227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 0.5 g daily for 29 days
Number of subjects: 40
Study 20935227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 1.0 g daily for 29 days
Number of subjects: 40
Study 20935227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 2.5 g daily for 29 days
Number of subjects: 40
Study 20935227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 5.0 g daily for 29 days
Number of subjects: 40
Study 20937120 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT and carbon ion boost (24 GyE carbon ions in 8 fractions and IMRT 50 Gy at 2.0 Gy/fraction)
Number of subjects: 54
Study 20937930 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic symptom burden measured using a 22-item scale.
Number of subjects: 405
Study 20937945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal and intravenous administration of autologous mesenchymal stem cells (MSCs). Mean (SD) of 63.2 × 10(6) (2.5 × 10(6)) MSCs injected. Follow-up ≤25 months.
Number of subjects: 34
Study 20938098 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (aspirin 100-200mg + clopidogrel 75 mg daily)
Number of subjects: 823
Study 20938098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinued at 3 months
Number of subjects: 823
Study 20938098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel continued for longer than 3 months
Number of subjects: 823
Study 20939723 — intervention group
Group type: EXPERIMENTAL
Intervention: Express LD Vascular stent
Number of subjects: 151
Study 20939732 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 8
Study 20940416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor cells from lymph nodes (LN)
Number of subjects: 24
Study 20940416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor proliferation quantified by E2F and c-MYC target genes and Ki67 staining
Number of subjects: 24
Study 20943702 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception SHBG levels
Number of subjects: 50
Study 20943702 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference, BMI, blood pressure, plasma glucose, insulin, HOMA-IR
Number of subjects: 50
Study 20943702 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma SHBG
Number of subjects: 50
Study 20943799 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D [25(OH)D] concentrations measured during winter
Number of subjects: 510
Study 20943799 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D [25(OH)D] concentrations measured during summer
Number of subjects: 510
Study 20943799 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variation in 25(OH)D concentrations
Number of subjects: 510
Study 20946651 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Concerns Inventory interview plus treatment as usual
Number of subjects: 100
Study 20946651 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 100
Study 20947286 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily with 12 weeks of behavioral counseling
Number of subjects: 32
Study 20948452 — intervention group
Group type: EXPERIMENTAL
Intervention: F-HX4 (422±142 MBq in humans; 189±3 MBq in monkeys)
Number of subjects: 7
Study 20950306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg) monotherapy
Number of subjects: 42
Study 20950392 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 20952478 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 20952514 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2
Number of subjects: 16
Study 20952514 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m2
Number of subjects: 16
Study 20952517 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal cytarabine (50 mg) given intrathecally together with systemic or intrathecal dexamethasone once every 2 weeks
Number of subjects: 19
Study 20952518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 50
Study 20952687 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB Treg infusion (0.1-30 × 10(5) UCB Treg/kg)
Number of subjects: 23
Study 20952687 — intervention group
Group type: COMPARATOR
Intervention: Historical controls without Treg
Number of subjects: 23
Study 20955442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (160/80 mg at weeks 0/2 for induction, 40 mg every other week for maintenance)
Number of subjects: 673
Study 20955442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 673
Study 20955461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib vaccination (universal vaccination introduced in 1992)
Number of subjects: 5703
Study 20955619 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli RNA fragments (20, 40, or 60 mg starting dose, escalated to a maximum of 80 mg)
Number of subjects: 30
Study 20955619 — intervention group
Group type: COMPARATOR
Intervention: Yeast RNA fragments (20, 40, or 60 mg starting dose, escalated to a maximum of 80 mg)
Number of subjects: 30
Study 20955619 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli RNA fragments (60 and 80 mg doses)
Number of subjects: 30
Study 20955704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 85
Study 20956472 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg orally twice a day)
Number of subjects: 14
Study 20956472 — intervention group
Group type: COMPARATOR
Intervention: non-neoadjuvant treatment
Number of subjects: 14
Study 20956472 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 14
Study 20956633 — intervention group
Group type: EXPERIMENTAL
Intervention: MelaFind
Number of subjects: 1383
Study 20956633 — intervention group
Group type: EXPERIMENTAL
Intervention: MelaFind (including borderline lesions)
Number of subjects: 1383
Study 20956633 — intervention group
Group type: COMPARATOR
Intervention: Dermatologists
Number of subjects: 1383
Study 20956641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status in patients with BCNS
Number of subjects: 41
Study 20956641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in patients with BCNS
Number of subjects: 41
Study 20956641 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of vitamin D deficiency in patients with BCNS
Number of subjects: 41
Study 20956641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in overweight patients with BCNS
Number of subjects: 41
Study 20956641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in patients with BCNS by season
Number of subjects: 41
Study 20956803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-adapted subclones of MCL cell lines JEKO and HBL2
Number of subjects: 0
Study 20956803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-adapted subclones
Number of subjects: 0
Study 20956803 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 0
Study 20956803 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of IRF4
Number of subjects: 0
Study 20956803 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmacytic differentiation
Number of subjects: 0
Study 20956803 — intervention group
Group type: COMPARATOR
Intervention: Intrinsically bortezomib-resistant MCL cell lines and primary tumor cells
Number of subjects: 0
Study 20958972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held fan (HHF)
Number of subjects: 70
Study 20958972 — intervention group
Group type: COMPARATOR
Intervention: Wristband
Number of subjects: 70
Study 20958975 — intervention group
Group type: EXPERIMENTAL
Intervention: Legal use of benzodiazepines before admission
Number of subjects: 227
Study 20958975 — intervention group
Group type: EXPERIMENTAL
Intervention: Illegal use of benzodiazepines before admission
Number of subjects: 227
Study 20958975 — intervention group
Group type: COMPARATOR
Intervention: No use of benzodiazepines before admission
Number of subjects: 227
Study 20958975 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines as adjuvant therapy
Number of subjects: 227
Study 20961630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived stem cells
Number of subjects: 0
Study 20961630 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20961818 — intervention group
Group type: EXPERIMENTAL
Intervention: AquADEKs® softgels daily for 12 weeks
Number of subjects: 14
Study 20961818 — intervention group
Group type: EXPERIMENTAL
Intervention: AquADEKs® softgels
Number of subjects: 14
Study 20961907 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment (specifics not provided)
Number of subjects: 346
Study 20961907 — intervention group
Group type: COMPARATOR
Intervention: CMV prophylaxis
Number of subjects: 346
Study 20961907 — intervention group
Group type: COMPARATOR
Intervention: Antilymphocyte antibody administration
Number of subjects: 346
Study 20962148 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg/d cholecalciferol supplementation for 4 weeks
Number of subjects: 11
Study 20962148 — intervention group
Group type: COMPARATOR
Intervention: Controlled intake providing 5 μg vitamin D and 1117 mg Ca/d
Number of subjects: 11
Study 20962157 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary carbohydrate intake
Number of subjects: 153
Study 20962157 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary total sugar intake
Number of subjects: 153
Study 20962157 — intervention group
Group type: COMPARATOR
Intervention: Dietary variables
Number of subjects: 153
Study 20964499 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg/day)
Number of subjects: 53
Study 20964499 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide (300 mg/day)
Number of subjects: 53
Study 20965184 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic gastroparesis (IG) patients with severe delay in gastric emptying (>35% retention at 4 hours)
Number of subjects: 243
Study 20965184 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with idiopathic gastroparesis
Number of subjects: 243
Study 20965184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute-onset IG
Number of subjects: 243
Study 20965184 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients with IG
Number of subjects: 243
Study 20965184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe delay in gastric emptying
Number of subjects: 243
Study 20965184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IG
Number of subjects: 243
Study 20965491 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal prolapse repair using partially absorbable mesh
Number of subjects: 127
Study 20965785 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib discontinuation
Number of subjects: 100
Study 20965785 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib reintroduction after relapse
Number of subjects: 100
Study 20966039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen treatment for symptomatic familial pulmonary fibrosis
Number of subjects: 2
Study 20966039 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic observation
Number of subjects: 2
Study 20966039 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT scan, pulmonary function tests, BAL analysis
Number of subjects: 2
Study 20966039 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic sequencing and analyses
Number of subjects: 2
Study 20967254 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening based on presence of additional cardiovascular risk factors (n=431)
Number of subjects: 1191
Study 20967254 — intervention group
Group type: COMPARATOR
Intervention: Screening for presence of albuminuria first (n=238)
Number of subjects: 1191
Study 20967254 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall screening for albuminuria in apparently healthy population
Number of subjects: 1191
Study 20967484 — intervention group
Group type: EXPERIMENTAL
Intervention: UCN-01 at 90 mg/m² over 3 h on cycle 1, reduced to 45 mg/m² over 3 h for subsequent cycles, every 21 days
Number of subjects: 17
Study 20974302 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa (Boostrix™, GlaxoSmithKline Biologicals)
Number of subjects: 164
Study 20976246 — intervention group
Group type: EXPERIMENTAL
Intervention: RareCover algorithm applied to re-sequencing data from FAAH and MGLL genes.
Number of subjects: 289
Study 20976246 — intervention group
Group type: COMPARATOR
Intervention: RareCover algorithm
Number of subjects: 289
Study 20976536 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight women
Number of subjects: 704
Study 20976536 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 704
Study 20977712 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 81
Study 20977712 — intervention group
Group type: COMPARATOR
Intervention: Exclusive replacement feeding (ERF)
Number of subjects: 81
Study 20977712 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 81
Study 20977712 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal education
Number of subjects: 81
Study 20977716 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention for exclusive infant feeding
Number of subjects: 0
Study 20977715 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual peer counselling (5 visits: before childbirth and during weeks 1, 4, 7, and 10 after childbirth)
Number of subjects: 370
Study 20977715 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual peer counselling (5 visits)
Number of subjects: 370
Study 20977715 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual peer counselling
Number of subjects: 370
Study 20978227 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based coping skills (VCS) training with telephone coaching
Number of subjects: 116
Study 20978227 — intervention group
Group type: COMPARATOR
Intervention: Wait List control condition
Number of subjects: 116
Study 20978276 — intervention group
Group type: EXPERIMENTAL
Intervention: Marqibo (vincristine sulfate liposome injection, VSLI)
Number of subjects: 0
Study 20979469 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066) at a dose of 250 mg twice daily in 28-day cycles
Number of subjects: 82
Study 20979472 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066, Pfizer)
Number of subjects: 1
Study 20979472 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1
Study 20980172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine thrombin product exposure (historical surgical procedure)
Number of subjects: 204
Study 20980487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher saturated fatty acid consumption
Number of subjects: 137486
Study 20980487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher monounsaturated fatty acid intake
Number of subjects: 137486
Study 20980487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher polyunsaturated fatty acid intake
Number of subjects: 137486
Study 20980487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of marine n-3 fatty acids
Number of subjects: 137486
Study 20980487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher n-6 fatty acid intake
Number of subjects: 137486
Study 20980658 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-based heme meal (intrinsically labeled (58)Fe pork)
Number of subjects: 29
Study 20980658 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate ((57)Fe)
Number of subjects: 29
Study 20980658 — intervention group
Group type: COMPARATOR
Intervention: Nonheme iron
Number of subjects: 29
Study 20980658 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme iron
Number of subjects: 29
Study 20980795 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA) after Dose 1
Number of subjects: 100
Study 20980795 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA) after Dose 2
Number of subjects: 100
Study 20980795 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA)
Number of subjects: 100
Study 20980933 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal conjugate vaccine (PHiD-CV)
Number of subjects: 0
Study 20980933 — intervention group
Group type: EXPERIMENTAL
Intervention: 7vCRM
Number of subjects: 0
Study 20980933 — intervention group
Group type: COMPARATOR
Intervention: DTPw-HBV/Hib and poliovirus vaccines
Number of subjects: 0
Study 20981430 — intervention group
Group type: EXPERIMENTAL
Intervention: GUCH patients
Number of subjects: 104
Study 20981545 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP) plus gemcitabine (1,000 mg/m2 on days 1, 8, and 15 every 28 days)
Number of subjects: 33
Study 20981545 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP) plus gemcitabine
Number of subjects: 33
Study 21028955 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 2500
Study 21028955 — intervention group
Group type: COMPARATOR
Intervention: Inactivated vaccine
Number of subjects: 2500
Study 21030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic vagus nerve stimulation (VNS) with CardioFit implantable system
Number of subjects: 32
Study 21030492 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-pipe smoking (WPS) for 30 minutes
Number of subjects: 45
Study 21030496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks) and fotemustine (100 mg/m² on days 1, 8, and 15, repeated after 4 weeks)
Number of subjects: 20
Study 21030496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus fotemustine
Number of subjects: 20
Study 21030496 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine (in vitro)
Number of subjects: 20